H.R. 2821

119th Congress

Introduced

FDA Modernization Act 3.0

Sponsored byRepublican:Rep. Carter, Earl L. "Buddy" [R-GA-1]GA· Introduced 10 April 2025
Open on Congress.gov

41

Cosponsors

18

Actions

0

Amendments

1

Committees

—

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 0 of 0
Latest action

Received in the Senate.

21 July 2026·2 days ago

Summary

Introduced in House · Updated 15 July 2026

FDA Modernization Act 3.0

This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. 

The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. 

The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule. 

Timeline

18 actions

  1. Received in the Senate.

    21 July 2026 · IntroReferral

  2. Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.

    20 July 2026 · Floor

  3. On motion to suspend the rules and pass the bill Agreed to by voice vote.

    20 July 2026 · Floor

  4. Motion to reconsider laid on the table Agreed to without objection.

    20 July 2026 · Floor

  5. Mr. Guthrie moved to suspend the rules and pass the bill.

    20 July 2026 · Floor

  6. Considered under suspension of the rules.

    20 July 2026 · Floor

  7. Mr. Guthrie moved to suspend the rules and pass the bill.

    20 July 2026 · Floor

  8. DEBATE - The House proceeded with forty minutes of debate on H.R. 2821.

    20 July 2026 · Floor

  9. Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

    18 June 2026 · Committee

  10. Placed on the Union Calendar, Calendar No. 614.

    18 June 2026 · Calendars

  11. Placed on the Union Calendar, Calendar No. 614.

    18 June 2026 · Calendars

  12. Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

    18 June 2026 · Committee

  13. Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

    18 June 2026 · Committee

  14. Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

    18 June 2026 · Committee

  15. Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

    18 June 2026 · Committee

  16. Committee Consideration and Mark-up Session Held

    21 May 2026 · Committee

  17. Committee Consideration and Mark-up Session Held

    21 May 2026 · Committee

  18. Committee Consideration and Mark-up Session Held

    21 May 2026 · Committee

  19. Committee Consideration and Mark-up Session Held

    21 May 2026 · Committee

  20. Ordered to be Reported by the Yeas and Nays: 44 - 0.

    21 May 2026 · Committee

Sponsorship

41 cosponsors

Sponsor

Republican:Rep. Carter, Earl L. "Buddy" [R-GA-1]GA

Cosponsors

  • Democrat2151%
  • Republican2049%

Classification

Policy area

Health

Legislative subjects

Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationMedical researchResearch administration and funding

Committees

1

  • Energy and Commerce Committee

    House · Standing

    • Referred To10 Apr 2025
    • Markup By21 May 2026
    • Reported By18 Jun 2026

    • Health Subcommittee

      • Referred to10 Apr 2026
      • Markup by13 May 2026
      • Reported by13 May 2026

Reports

Cosponsor momentum

Cumulative over time

Cosponsors grew from 5 on 10 April 2025 to 41 on 2 June 2026.

Pelosi Tracker
Follow on XJoin our Discord
PoliticiansBillsPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.